PL3377534T3 - Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4 - Google Patents

Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4

Info

Publication number
PL3377534T3
PL3377534T3 PL16819718.4T PL16819718T PL3377534T3 PL 3377534 T3 PL3377534 T3 PL 3377534T3 PL 16819718 T PL16819718 T PL 16819718T PL 3377534 T3 PL3377534 T3 PL 3377534T3
Authority
PL
Poland
Prior art keywords
antibody
ctla
treatment
combination
lung cancer
Prior art date
Application number
PL16819718.4T
Other languages
English (en)
Inventor
Nathan E. FAITH
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57680484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3377534(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL3377534T3 publication Critical patent/PL3377534T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL16819718.4T 2015-11-18 2016-11-18 Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4 PL3377534T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257139P 2015-11-18 2015-11-18
US201662345314P 2016-06-03 2016-06-03
PCT/US2016/062884 WO2017087870A1 (en) 2015-11-18 2016-11-18 Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody

Publications (1)

Publication Number Publication Date
PL3377534T3 true PL3377534T3 (pl) 2025-09-01

Family

ID=57680484

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819718.4T PL3377534T3 (pl) 2015-11-18 2016-11-18 Leczenie raka płuc kombinacją przeciwciała anty-pd-1 i przeciwciała anty-ctla-4

Country Status (18)

Country Link
US (3) US11072657B2 (pl)
EP (2) EP4609915A3 (pl)
JP (3) JP2018538263A (pl)
KR (2) KR20260020215A (pl)
CN (1) CN108350081A (pl)
DK (1) DK3377534T3 (pl)
ES (1) ES3034582T3 (pl)
FI (1) FI3377534T3 (pl)
HR (1) HRP20250902T1 (pl)
HU (1) HUE072729T2 (pl)
LT (1) LT3377534T (pl)
PL (1) PL3377534T3 (pl)
PT (1) PT3377534T (pl)
RS (1) RS67037B1 (pl)
SI (1) SI3377534T1 (pl)
SM (1) SMT202500282T1 (pl)
TW (3) TWI912619B (pl)
WO (1) WO2017087870A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
SMT202500282T1 (it) 2015-11-18 2025-09-12 Bristol Myers Squibb Co Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4
JP7258747B2 (ja) * 2016-10-28 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー 抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
US20210179714A1 (en) * 2017-11-07 2021-06-17 Memorial Sloan Kettering Cancer Center Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020185739A1 (en) * 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
WO2020185722A2 (en) * 2019-03-13 2020-09-17 Merck Sharp & Dohme Corp. Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents
WO2020198676A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
BR112023000826A2 (pt) * 2020-07-21 2023-02-07 Shanghai Junshi Biosciences Co Ltd Anticorpo anti-ctla-4 e uso do mesmo
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법
WO2022178319A1 (en) * 2021-02-18 2022-08-25 Qilu Puget Sound Biotherapeutics Corporation Combinations of anti-pd1 and anti-ctla4 antibodies
US20250376525A1 (en) * 2022-06-28 2025-12-11 Qilu Pharmaceutical Co., Ltd. Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PL354286A1 (pl) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Receptor PD-1 dla B7-4 i jego zastosowaniaReceptor PD-1 dla B7-4 i jego zastosowania
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011045704A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
AU2013296919A1 (en) * 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
PL3102605T3 (pl) 2014-02-04 2019-06-28 Pfizer Inc. Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu
WO2015176033A1 (en) * 2014-05-15 2015-11-19 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
EP3288565A4 (en) * 2015-04-30 2019-02-13 Histogen, Inc. EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER OR IMMUNE DISEASES
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
EP3322731B1 (en) * 2015-07-14 2021-01-13 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
SMT202500282T1 (it) * 2015-11-18 2025-09-12 Bristol Myers Squibb Co Trattamento del cancro del polmone utilizzando una combinazione di un anticorpo anti-pd-1 e di un anticorpo anti-ctla-4
US20210206854A1 (en) 2016-01-27 2021-07-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP7069032B2 (ja) * 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
CN109475634A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
CN109476753A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗肿瘤的方法的抗-pd-1抗体
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2020086724A1 (en) * 2018-10-23 2020-04-30 Bristol-Myers Squibb Company Methods of treating tumor

Also Published As

Publication number Publication date
LT3377534T (lt) 2025-08-11
TWI821748B (zh) 2023-11-11
PT3377534T (pt) 2025-07-10
US20220017619A1 (en) 2022-01-20
EP3377534B1 (en) 2025-06-18
SMT202500282T1 (it) 2025-09-12
SI3377534T1 (sl) 2025-09-30
CN108350081A (zh) 2018-07-31
HRP20250902T1 (hr) 2025-09-26
KR20180071386A (ko) 2018-06-27
ES3034582T3 (en) 2025-08-20
US12528865B2 (en) 2026-01-20
EP4609915A2 (en) 2025-09-03
RS67037B1 (sr) 2025-08-29
KR20260020215A (ko) 2026-02-10
US20180371092A1 (en) 2018-12-27
JP2018538263A (ja) 2018-12-27
JP2022068352A (ja) 2022-05-09
JP2025029025A (ja) 2025-03-05
HUE072729T2 (hu) 2025-12-28
EP4609915A3 (en) 2025-11-19
TW202408573A (zh) 2024-03-01
DK3377534T3 (da) 2025-08-18
TWI912619B (zh) 2026-01-21
WO2017087870A1 (en) 2017-05-26
US11072657B2 (en) 2021-07-27
TW201731527A (zh) 2017-09-16
FI3377534T3 (fi) 2025-08-22
EP3377534A1 (en) 2018-09-26
TWI795347B (zh) 2023-03-11
TW202227132A (zh) 2022-07-16
US20250154257A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
SI3377534T1 (sl) Zdravljenje pljučnega raka s kombinacijo protitelesa anti-pd-1 in protitelesa anti- ctla-4
IL282962A (en) Anti-PD-1 antibodies and methods of using them
IL268479A (en) Anti-PD-1 antibodies for the treatment of lung cancer
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL276481B (en) Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer
IL262892A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
IL259924A (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
IL253462A0 (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL252280A0 (en) Anti pd-1 antibodies and methods of using them
SG10201913500TA (en) Anti-ctla-4 antibodies and methods of use thereof
IL259713B2 (en) Anti-DR5 antibodies and methods of using them
SI4339615T1 (sl) Protitelesa anti-pd-1 za uporabo pri zdravljenju raka
IL307850A (en) A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
IL266990A (en) Methods for treating cancer using anti-pd-l1 antibodies and antiandrogens
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
HK40018984A (en) Anti-pd-1 antibodies for treatment of lung cancer